CERo Therapeutics Doses Third Patient in Cohort 2 of Phase 1 CER-1236 Trial
Study will advance into expanded patient populations with myelodysplastic syndrome (MDS) and myelofibrosis (MF) SOUTH SAN FRANCISCO, Calif., April 15, 2026: CERo Therapeutics Holdings, Inc., (OTCQB: CERO) (“CERo” or the “Company”) an innovative…